RGR. I. Gouspanov

R. I. Gouspanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


R. I. Gouspanov has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Robot-assisted radical nephrectomy with thrombectomy using fluorescence guidance

    by A. G. Pavlenko, D. S. Kobzev, R. I. Guspanov, A. S. Maksimova, N. O. Demchenkov, D. V. Tizo, A. A. Nemenov, S. V. Kotov, А. Г. Павленко, Д. С. Кобзев, et al.

    Background. Radical nephrectomy with thrombectomy for renal cell carcinoma complicated by inferior vena cava (IVC) tumor thrombus requires precise intraoperative identification of the thrombus borders. Indocyanine green (ICG) fluorescence-guided navigation may facilitate localization of the thrombus tip during surgery and help determine the required extent of cavotomy. Aim. To assess the feasibility of ICG fluorescence imaging during robot-assisted radical nephrectomy with thrombectomy and to describe the key steps of the surgical technique. Materials and methods. The study included five patients with cT3b renal cell carcinoma and IVC tumor thrombus. All patients underwent robotassisted surgery with intravenous ICG administration for thrombus visualization in near-infrared range. The ability to identify the thrombus tip, operative time, blood loss, postoperative length of stay, and surgical margin status were analyzed. The surgical technique is described in detail using an example of a patient with right-sided renal tumor and a Mayo level I tumor thrombus. Results. The tip of the tumor thrombus was successfully visualized in all five patients. The mean operative time was 266.20 ± 74.56 min, median blood loss was 30 mL (Q 1 –Q 3 : 10–100 mL), and the mean postoperative length of stay was 10.80 ± 6.30 days. No positive surgical margins were observed. The obtained results were comparable to scientific literature data. ICG fluorescence imaging allowed to clarify thrombus extent and the required length of cavotomy; for a short tumor thrombus, kidney traction resulted in displacement of the thrombus into the renal vein, which allowed to avoid cavotomy. Repeat ICG administration was also used to further assess the integrity of the vascular suture line. Conclusion. The use of indocyanine green fluorescence-guided navigation during robot-assisted radical nephrectomy with thrombectomy is technically feasible. This approach enables real-time delineation of the cranial margin and extent of the tumor thrombus, optimization of the required cavotomy, and, in selected cases, avoidance of cavotomy altogether. The proposed technique may therefore represent a promising direction for further refinement of surgical management of renal cell carcinoma complicated by tumor thrombus.

  • Open Access

    Intraoperative blood loss and warm ischemia time as independent predictors of positive surgical margins following partial nephrectomy

    by A. G. Pavlenko, D. V. Tyzo, R. I. Guspanov, D. S. Kobzev, A. G. Yusufov, S. V. Kotov, А. Г. Павленко, Д. В. Тызьо, Р. И. Гуспанов, Д. С. Кобзев, et al.

    Introduction. The presence of a positive surgical margin (PSM; R1 resection) following partial nephrectomy is associated with inferior oncological outcomes. Identification of risk factors for PSM and targeted optimization of modifiable variables may improve the surgical management of renal cell carcinoma and enhance long-term oncological outcomes. Objective. To identify risk factors for PSM following partial nephrectomy performed under warm ischemia, determine which of these factors are potentially modifiable, and evaluate the potential for reducing the incidence of PSM through targeted perioperative management. Materials & methods. A retrospective single-center study was conducted including 570 patients with localized renal cell carcinoma (clinical stages cT1–T2) who underwent partial nephrectomy between 2023 and 2025. Procedures were performed under warm ischemia using laparoscopic, retroperitoneoscopic, open, or robot-assisted approaches. Demographic, clinical, and pathological characteristics, the R.E.N.A.L. nephrometry score, surgical complexity, and key perioperative parameters—including warm ischemia time, estimated blood loss, incidence of collecting system injury, and PSM rate—were analyzed. Multivariable logistic regression, multivariable linear regression, and receiver operating characteristic (ROC) curve analyses were performed to identify independent predictors. Results . The overall incidence of PSM was 6.3% (n = 36). On univariable analysis, PSM was associated with larger tumor size, clinical stage cT1b, a higher R.E.N.A.L. nephrometry score, greater surgical complexity, prolonged warm ischemia time, and increased intraoperative blood loss. Multivariable analysis identified warm ischemia time and intraoperative blood loss as independent predictors of PSM. Threshold values associated with an increased risk of PSM were 28 minutes for warm ischemia time and 100 mL for intraoperative blood loss. Blood loss ≥100 mL was also associated with an increased risk of collecting system injury. Independent predictors of increased intraoperative blood loss included tumor size, the presence of atherosclerosis, operative time, warm ischemia time, surgical maneuver (tumor resection), and the renal artery-to-aorta diameter ratio (RA/Ao). An RA/Ao ratio ≥29% was found to predict intraoperative blood loss ≥100 mL. Conclusions. Warm ischemia time and intraoperative blood loss are independent predictors of PSM following partial nephrectomy performed under warm ischemia. Among these, intraoperative blood loss represents the only modifiable risk factor, underscoring the importance of meticulous preoperative planning and rigorous intraoperative hemostatic control. Attention should be paid to patients with atherosclerosis and an RA/Ao ratio ≥29%, as they are at increased risk of significant blood loss. Implementation of these strategies may reduce the incidence of PSM and improve oncological outcomes following partial nephrectomy. Further validation of these findings in prospective multicenter studies is warranted.

  • Open Access

    Repeat biopsy techniques and outcomes in the detection of clinically significant prostate cancer

    by M. S. Zhilov, R. I. Gouspanov, A. G. Yusufov, S. V. Kotov

    Introduction. Prostate biopsy remains the definitive standard for confirming malignancy in the prostate. However, a negative initial biopsy does not rule out the presence of prostate cancer (PCa) during subsequent follow-up. This review provides an overview of current repeat biopsy techniques and assesses their diagnostic accuracy for clinically significant PCa (csPCa). Objective. To study various methods of repeated biopsy and evaluate the results of diagnosis of csPCa. Materials & Methods. A review of PubMed, eLibrary electronic databases was conducted from 2000 to 2024 to identify all relevant studies. The electronic search was limited to Russian and English, and the keywords used were: repeat prostate biopsy, clinically significant prostate cancer, fusion biopsy. Results. Currently, the following techniques can be used to perform a repeat prostate biopsy: saturation biopsy, micro-ultrasound, histoscanning and fusion biopsy. Saturation biopsy is associated with an increase in the number of complications, histoscanning has not shown high efficiency, micro-ultrasound is not so common and is limited by the number of studies. The advantage of diagnosing csPCa in patients with a previous negative histological conclusion is currently behind fusion biopsy. One of the advantages is the ability to choose one of three execution techniques: fusion, cognitive and in bore. Conclusions. Fusion technique shows the best results of the effectiveness of the diagnosis of csPCa with repeated biopsy. According to the literature, various methods of performing fusion biopsies are comparable to each other.

  • Open Access

    Results of using targeted methods in repeat prostate biopsy in patients with negative results of primary systemic biopsy

    by M. S. Zhilov, A. G. Yusufov, R. I. Guspanov, S. V. Kotov

    Background. Biopsy is the standard for prostate cancer (PCa) diagnostics. The false negative rate of 12-core biopsy is about 30 %. To improve the quality of detection of clinically significant PCa (csPCa) (ISUP (International Society of Urological Pathology) score 2 or more) during repeat biopsy, it is possible to use targeted diagnostic methods, such as HistoScanning (HS), cognitive fusion biopsy, hardware fusion biopsy. Aim. To compare targeted prostate biopsy methods: HS, cognitive fusion, hardware fusion biopsy for the diagnosis of csPCa during repeat biopsy in patients with negative primary biopsy result. Materials and methods. A prospective comparative study was conducted. The study included 320 men with suspected PCa after negative primary biopsy. Median age was 68 years, PSA level was 9.1 ng/mL, prostate volume was 57 cm2, PSA density was 0.15 ng/ml/cm2. Patients were divided into three groups depending on repeat biopsy method: group 1 – HS, group 2 – cognitive fusion biopsy, group 3 – hardware fusion biopsy; the groups were comparable with each other. Results. PCa was diagnosed after repeat biopsy using HS, cognitive fusion, hardware fusion biopsy in 25.4, 45.5, 44.2 % of cases, respectively; csPCa was diagnosed in 4.5, 22.2, 18.2 % of cases, respectively. In all groups, PCa and csPCa were most often diagnosed with lesions in both target and standard biopsies. The use of targeting in the HS group did not provide an advantage in diagnostics. In the hardware fusion biopsy group, in the absence of cancer in standard cores, csPCa was diagnosed more often in targeted biopsies, compared with the cognitive fusion technique (11.8 % versus 7.5 %). With both fusion biopsy techniques, more malignant forms of PCa were diagnosed in targeted biopsies, compared with standard cores, however, due to standard cores, 23.5 % of PCa cases were not missed, of which 3.75 % were csPCa. The use of transrectal cognitive fusion technique showed a comparable result with perineal hardware fusion biopsy for diagnosing transition zone cancer. Conclusion. The HS technique did not show advantages in diagnosing PCa during repeat biopsy. The use of cognitive fusion and hardware fusion techniques allows to improve diagnostics of both PCa and csPCa during repeat biopsy. According to our data, it is recommended to use targeted cores in addition to the standard ones. The use of cognitive fusion biopsy showed comparable results with hardware fusion in diagnostics of transition zone prostate cancer.

  • Open Access

    Overactive bladder following surgical intervention for benign prostatic hyperplasia: treatment outcomes in routine clinical practice

    by D. A. Bogdanov, A. G. Yusufov, R. I. Guspanov, S. V. Kotov

    Introduction. Various surgical methods for the treatment of benign prostatic hyperplasia (BPH) effectively alleviate voiding symptoms and improve urinary flow quality. However, patient satisfaction often decreases due to the persistence of storage symptoms following surgical intervention.Objective. To determine the prevalence of persistent storage symptoms and overactive bladder (OAB), optimal approaches to the treatment of symptoms after surgical treatment of BPH in clinical practice.Materials & methods. The study included 94 patients aged 53 – 79 years who underwent surgery for BPH, with persistent storage symptoms in 1 – 3 months after surgery (IPSS-storage score ≥ 3). The patients underwent urodynamic examination. In the case of persistent symptoms without confirmed OAB, behavioral therapy was performed (group 1). In case of detrusor overactivity («dry» OAB), patients were prescribed medication solifenacin 5 mg daily (group 2), in case of terminal detrusor overactivity, urgent urinary incontinence («wet» OAB), combination therapy solifenacin 5 mg + mirabegron 50 mg (group 3) was prescribed.Results. Patient characteristics in the preoperative period showed no statistically significant differences between groups regarding age, urodynamic parameters, and lower urinary tract symptoms (LUTS) as assessed by the IPSS questionnaire. At the initiation of therapy, the median storage symptom scores were 4, 8, and 9 points in groups 1, 2, and 3, respectively. Both the behavioral and pharmacological therapy groups demonstrated a statistically significant reduction in the severity of storage symptoms over time (p < 0.001). After 12 weeks, the median storage symptom scores were 3 points in group 1, 4 points in group 2, and 6 points in group 3. Urgent incontinence was eliminated in group 3 after treatment. By 12 months after surgical treatment and drug therapy, the irritative symptoms and the number of nocturia episodes approach equal values in all groups (p > 0.05). Patients from the drug therapy groups showed high adherence to therapy, among them there were no significant side effects requiring discontinuation of therapy.Conclusion. The use of pharmacological therapy with M-cholinergic antagonists and/or β3-adrenoceptor agonists in the postoperative period in patients with confirmed detrusor overactivity contributes to a reduction in urgency symptoms and enhances patient treatment satisfaction. In the absence of detrusor overactivity or with an IPSS storage score ≤ 6, behavioral therapy represents a viable alternative to pharmacological treatment.


  • Open Access

    Molecular genetic subtypes of non-muscle-invasive bladder cancer: their impact on disease prognosis

    by Sh. M. Sargsian, S. V. Kotov, A. R. Zaretskiy, A. S. Badlaeva, R. I. Guspanov, С. А. Пульбере, D. V. Litvin

    Introduction. Bladder cancer is one of the most prevalent malignancies, characterized by high rates of recurrence and progression—even in its superficial forms, such as non-muscle-invasive bladder cancer (NMIBC). Recent research has increasingly focused on the molecular and genetic profiles of these tumors, as these factors, together with tumor grade and stage, play a crucial role in determining disease prognosis.Objective. To investigate the impact of molecular genetic subtypes in NMIBC on disease prognosis and assess the feasibility of their evaluation in routine clinical practice.Materials & methods. We conducted a retrospective study that included 162 patients with newly diagnosed primary NMIBC treated at the University Urology Clinic between 2011 and 2021. Subsequently, an IHC study of postoperative material from patients with antibodies to GATA3, CK5/6 and FOXA1 was carried out. Subsequently, patients were monitored, and the percentage of relapses and progressions was assessed depending on the molecular genetic subtype. The median follow-up was 36 months.Results. Based on IHC results, tumors were classified into four subtypes: luminal (96; 59.3%), luminal-like (51; 31.5%), intermediate (5; 3.1%), and basal-squamous-like (10; 6.2%). During follow-up, recurrence and progression rates differed significantly between groups. Luminal tumors exhibited low recurrence (33.3%) and progression rates (2.1%), while luminal-like tumors showed higher recurrence (54.9%) but maintained low progression risk (5.9%). In contrast, intermediate and basal-squamous-like subtypes were associated with aggressive behavior: both demonstrated high recurrence rates (100% and 90.0%, respectively) and elevated progression risk (25.0% and 50.0%, respectively) (p < 0.05).Conclusion. Basal-squamous-like tumors demonstrate the worst prognosis in terms of disease recurrence and progression, necessitating more aggressive treatment, whereas luminal tumors are associated with the most favorable outcomes.

  • Open Access

    Affective disorders before and after laser enucleation of the prostate

    by A. P. Semenov, A. G. Yusufov, R. I. Guspanov, S. V. Kotov

    Introduction. Lower urinary tract symptoms (LUTS), sexual dysfunction and psychological disorders coexist in the lives of older men. Evaluation of the prevalence of mood disorders and sexual dysfunction after surgical treatment is important to ensure a high quality of life for patients with LUTS.Objective. To analyse the incidence and severity of affective disorders in patients before and after laser enucleation of the prostate and to determine their association with LUTS and erectile dysfunction. Materials & methods. The study included 136 patients with benign prostatic hyperplasia treated with laser enucleation between 2018 and 2023. All the male participants were sexually active, and their erectile function was assessed at 11 points or higher according to the IIEF-5 scale. In addition to standard examination methods, all patients completed the IPSS, IIEF-5, and HADS questionnaires prior to surgery and 18 months postoperatively. The first stage of the study involved an investigation into the prevalence and severity of affective disorders both before and after surgical intervention, as well as determining their correlation with LUTS. The second stage focused on examining the relationship between affective disorders and sexual dysfunction. Patients were categorized into two groups based on the absence or presence of negative influence of LUTS on their quality of sexual life: group 1 (n = 70) — no influence, group 2 (n = 66) — influence is present.Results. Anxiety and depressive disorders of varying severity were found in 48 (35.3%) and 46 (33.8%) patients, respectively. It was found that the severity of both anxiety (r = 0.574; p < 0.001) and depressive disorders before surgical treatment correlated with LUTS (r = 0.590; p < 0.001), but after surgical treatment only anxiety disorder scores had a correlation with LUTS (r = 0.742; p < 0.001), and with irritative symptoms (r = 0.475; p < 0.001). Group 2 patients had lower IIEF-5 scores (18.0 vs. 21.0 points; p < 0.001) and were more likely to have anxiety and depressive disorders before surgical treatment (45.7 and 44.3% vs. 22.8 and 22.7%; p < 0.05), with significant improvement in erectile function and affective status after surgery, in contrast to group 1 patients, whose IIEF-5 scores and incidence of affective disorders did not change significantly.Conclusion. Patients with a predominantly irritative LUTS profile and a negative impact of urinary disturbances on sexual life are more susceptible to anxiety and depressive disorders. Consequently, evaluating their affective state is essential when treating men with LUTS to enhance their quality of life.

  • Open Access

    Complications and urinary disorders after surgical treatment of BPH by laser enucleation.

    by S.V. Kotov, Russia Moscow, D.A. Bogdanov, A.G. Yusufov, R.I. Guspanov, I.E. Mamaev

    Introduction. Benign prostatic hyperplasia (BPH) is a common disease in elderly men, manifested by symptoms of the lower urinary tract. Drug treatment of BPH often allows you to delay or even avoid performing surgery. Laser endoscopic enucleation, which shows excellent functional results regardless of the patient's age and prostate volume, can be considered the modern «gold standard» of surgical treatment of BPH. However, complications and urinary disorders after surgical treatment are also inherent in this method. The purpose of this article was to systematize information on the quality of urination and the preservation of symptoms of the lower urinary tract in patients after endoscopic enucleation of BPH. Materials and methods. The literature review was compiled from analyzed materials from three scientific databases (PubMed, Scopus and Web of Science, eLibrary), focusing on the following keywords: «laser enucleation», «lower urinary tract symptoms», «complications after enucleation of prostate». Results. The obtained results of many studies allow us to state the existence of a new «gold standard» of surgical treatment of BPH and to consider the possibility of introducing HoLEP into the standards of medical care for urological patients with BPH. In the postoperative period, long-term monitoring of patients is necessary. Currently, there are no clear standards for the necessary examinations and the timing of their implementation in the postoperative period. Conclusion. Laser enucleation is a reliable method of surgical treatment of LUTS due to BPH.


  • Open Access

    Comparison of en-bloc resection of the bladder wall and tumor with standard transurethral bladder resection in treatment of non-muscle invasive bladder cancer

    by S. V. Kotov, R. I. Guspanov, С. А. Пульбере, A. L. Khachatryan, Sh. M. Sargsian, Yu. P. Kraev, D. A. Samoylov

    Background. Bladder cancer currently poses a major challenge to urologic oncologists worldwide due to its high recurrence rates. Although the treatment of non-muscle invasive bladder cancer does not carry the same risks as the treatment of muscle invasive forms, frequent recurrences and subsequent tumor progression can lead to patients undergoing disabling organ-removing operations with great risk to life and health. Therefore, improvement of treatment methods for non-muscle invasive bladder cancer may make the quality of life of patients with these diseases better.Aim. To evaluate the safety and effectiveness of en-bloc transurethral resection of bladder tumor (eTURBT) compared with conventional TURBT (cTURBT) in the treatment of patients with non-muscle invasive bladder cancer.Materials and methods. The retrospective study included 197 patients with newly diagnosed primary non-muscle invasive bladder cancer who underwent eTURBT (n = 34) or cTURBT (n = 163) at the University Urology Clinic between 2011 and 2021. The groups did not have statistically significant differences in gender, age, and tumor characteristics. Median follow-up was 28.25 months.Results. Both groups had comparable perioperative indicators, but the quality of the material obtained after eTURBT was better than after cTURBT. Patients with adjuvant intravesical chemotherapy in the early postoperative period had better oncological results compared with patients without it (35.71 % recurrences and/or progression versus 49.12 %) (p 0.05). Additionally, in the eTURBT group the number of recurrences was significantly lower: 14.71 % versus 40.49 % (p 0.05).Conclusion. In the absence of contraindications for eTURBT, this method of surgical treatment of non-muscle invasive bladder cancer with adjuvant intravesical chemotherapy in the early postoperative period seems more promising with better oncological indicators.


  • Open Access

    Efficacy of Phlogenzyme® in men following transurethral laser enucleation of prostate hyperplasia: results of a randomized trial

    by S. V. Kotov, С. А. Пульбере, A. G. Yusufov, A. D. Bolotov, R. I. Guspanov, A. P. Semenov, D. A. Bogdanov

    Introduction. The most advanced and effective method of surgical treatment for benign prostatic hyperplasia (BPH) is transurethral laser enucleation of the prostate (tLEP). Recently, there has been a growing interest in exploring new approaches to reduce the risk of complications following tLEP.Objective. To evaluate the efficacy of using Phlogenzym® as part of a comprehensive treatment plan for patients following tLEP to reduce dysuria (urinary discomfort), leukocyturia (white blood cells in urine), and prevent infectious and fibrosis-related complications.Materials & methods. An open-label, randomized trial enrolled 105 patients undergoing tLEP. The patients were randomly assigned to two groups: the study group (n=50) received standard postoperative care in combination with Phlogenzym® for 30 days, while the control group (n=55) received standard care (α1-adrenergic blocker for 28 days) only. uring the follow-up period, which lasted for 1, 3, and 6 months postoperatively, complaints were evaluated using the IPSS-QoL, and IIEF-5 questionnaires, as well as indicators of urinalysis and urine culture, prostate volume measurements, residual urine volume, and uroflowmetry data.Results. Among all patients, the median preoperative values for prostate volume, IPSS, QoL score, and median peak urine flow rate were 90 cc, 18 points, 5 points, and 7.9 mL/s, respectively, with no significant differences between the groups. One month after surgery, in the study group, there was a more significant decrease in prostate volume (57% vs. 41%), although this difference was not statistically significant (p > 0.05). At the 6-month follow-up, bacteriuria was less common in the study group (42% vs. 67%), and there was a consistent trend toward a reduction in the incidence of fibrous complications, although these differences were not statistically significant either (p > 0.05). No adverse events occurred during the follow-up period.Conclusion. Our experience suggests that the use of Phlogenzym® is safe during the postoperative period following tLEP surgery. The use of this drug leads to a reduction in prostate volume postoperatively and significantly reduces the bacteriuria by the six-month follow-up. Additionally, there is a persistent positive trend towards reducing the overall incidence of fibrotic complications in the surgical site. The results achieved and the absence of significant side effects characterize Phlogenzym® as having a favorable clinical profile.